Phase II trial of axilla treatment after primary chemotherapy for breast cancer patients with sentinel lymph node metastases

Phase II trial of axilla treatment after primary chemotherapy for breast cancer patients with sentinel lymph node metastases - Axilla treatment after chemotherapy for sentinel node-positive breast cancer patients

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003900

Enrollment

Registered

2010-07-14

Start date

2010-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Sentinel node biopsy, primary chemotherapy, breast surgery with axillary lymph node dissection

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: T1-3N0M0 Invasive cancer pN1mi(sn) or pN1(sn)

Exclusion criteria

Exclusion criteria: Breast cancer patient during pregnancy Bilateral breast cancer Primary endocrine therapy

Design outcomes

Primary

Measure	Time frame
Positive rate of axillary nodes after primary chemtoherapy	—

Secondary

Measure	Time frame
5-year overall survival rate of breast cancer patients after primary chemotherapy	—

Countries

Japan

Contacts

Public ContactSatomi Yana

Japanese Society for Sentinel Node Navigation Surgery Office

yanas@sc.itc.keio.ac.jp03-3353-6440

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026